ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Prior treatment

• The patient has previously received Orenitram for more than 182 days.
• The patient is currently participating in an investigational drug or device study or has participated in a clinical study with an investigational product other than Orenitram in PAH within

Other

• Patients are ineligible for the registry if:

• Patients are eligible for the registry if:
• The patient voluntarily gives informed consent to participate in the study.
• The patient must be at least 18 years of age or older.
• The patient is prescribed Orenitram (per the package insert indication), and plans to initiate therapy with this medication or has been receiving Orenitram for 182 or fewer days.
• The patient agrees to dosing, prostacyclin-related AE of interest record keeping, survey participation during designated time periods, and recording any medication changes, use, for the duration of the study.
• The patient has the ability to answer surveys and use the diary in English.
• The patient must have an email address and be willing to access the PRO Portal.